TL;DR: Aetna modified CPB 1079 to establish coverage criteria for revakinagene taroretcel-lwey (Encelto), a gene-based intravitreal implant for Macular Telangiectasia Type 2, effective December 20, 2025. Here's what billing teams need to act on now.
Aetna, a CVS Health company, updated its Encelto coverage policy under CPB 1079 in the Aetna system, effective December 20, 2025. The primary billing code is HCPCS J3403 (revakinagene taroretcel-lwey, per implant), with implantation billed under CPT 67027. This is a high-complexity GCIT product — every claim runs through Aetna's dedicated Gene-based, Cellular & Other Innovative Therapies team, which means a different review process than standard prior authorization. If your ophthalmology or retinal surgery practice isn't set up for this pathway yet, you're already behind.
Quick-Reference Table
| Field | Detail |
|---|---|
| Payer | Aetna, a CVS Health company |
| Policy | Revakinagene Taroretcel-lwey (Encelto) — CPB 1079 |
| Policy Code | CPB 1079 |
| Change Type | Modified |
| Effective Date | December 20, 2025 |
| Impact Level | High — gene therapy with GCIT-specific precertification and site-of-care requirements |
| Specialties Affected | Ophthalmology, Retinal Surgery |
| Key Action | Confirm GCIT network designation and initiate precertification through Aetna's GCIT team before billing J3403 or CPT 67027 |
Aetna Encelto Coverage Criteria and Medical Necessity Requirements 2025
Revakinagene taroretcel-lwey (Encelto) billing under Aetna requires you to clear two separate gates before a claim has any chance of approval: medical necessity criteria and GCIT network compliance. Skipping either one will get your claim denied.
For medical necessity, Aetna covers Encelto for one indication only: idiopathic Macular Telangiectasia Type 2 (MacTel) in adult members. Coverage is limited to a one-time intravitreal implantation per affected eye. The policy summary was truncated in the public document, but the indication structure is specific — "adult members" is the floor, and MacTel Type 2 is the ceiling. There's no off-label coverage pathway in this CPB.
Precertification is mandatory for all Aetna participating providers and members in applicable plan designs. Call (866) 752-7021 or fax (888) 267-3277 to initiate. Statement of Medical Necessity forms are available through Aetna's Specialty Pharmacy Precertification portal. Do not bill J3403 without precertification in hand — that's a guaranteed claim denial.
The prior authorization process here is not your standard utilization management review. Encelto routes to Aetna's GCIT team, which applies additional scrutiny to gene-based and cellular therapies. Budget more time for review than you would for a typical biologic authorization. If your practice doesn't have experience with GCIT submissions, talk to your billing consultant before the first case.
Site of care is the other major compliance requirement. Unless the member's health plan has opted out, Encelto must be administered at an Aetna Institutes® GCIT Designated Network facility. Confirm your facility's GCIT network status before scheduling any procedure. Administering outside a designated site — even with all other criteria met — jeopardizes reimbursement entirely. Check the Aetna Institutes® GCIT Designated Networks list on Aetna's site directly.
Aetna Encelto Exclusions and Non-Covered Indications
This is where the real billing risk lives. Aetna's exclusion list for Encelto is long — 17 categories — and any single exclusion makes the member ineligible. Review this list against patient charts before precertification, not after.
The exclusions fall into four practical buckets: prior ocular interventions, concurrent ocular conditions, systemic factors, and anatomical findings on imaging.
Prior ocular interventions that disqualify a member:
| # | Excluded Procedure |
|---|---|
| 1 | Vitrectomy (CPT 67036–67043), penetrating keratoplasty (CPT 65730, 65750, 65755), trabeculectomy (CPT 66170, 66172), or trabeculoplasty (CPT 65855) |
| 2 | YAG laser capsulotomy (CPT 66821) within the past four weeks |
| 3 | Lens removal in the previous three months |
| 4 | Any prior Encelto treatment in the affected eye(s) |
| 5 | Intravitreal anti-VEGF therapy in the affected eye(s), or anti-VEGF in the non-affected eye within the past three months |
| 6 | Intravitreal steroid therapy for non-neovascular MacTel within the past three months |
Concurrent ocular conditions that disqualify a member:
| # | Excluded Procedure |
|---|---|
| 1 | Evidence of intraretinal or subretinal neovascularization (e.g., neovascular MacTel), with hemorrhage, hard exudate, or subretinal/intraretinal fluid in either eye |
| 2 | Central serous chorio-retinopathy in either eye |
| 3 | Pathologic myopia in either eye |
| 4 | Significant corneal or media opacities in either eye |
| 5 | Intraretinal hyperreflectivity on OCT in either eye |
| 6 | Ocular herpes virus history in either eye |
| 7 | Active ocular or periocular infection |
| 8 | Glaucoma |
| 9 | Severe nonproliferative or proliferative diabetic retinopathy |
| 10 | Uveitis |
Lens opacity thresholds (AREDS grading system):
| # | Excluded Procedure |
|---|---|
| 1 | Cortical opacity greater than standard 3 |
| 2 | Posterior subcapsular opacity greater than standard 2 |
| 3 | Nuclear opacity greater than standard 3 |
Systemic and medication factors:
| # | Excluded Procedure |
|---|---|
| 1 | Active chemotherapy (billed under HCPCS J8501–J9999) |
| 2 | Known hypersensitivity to Endothelial Serum Free Media (Endo-SFM) |
| 3 | Inability to temporarily discontinue antithrombotic therapy before surgery (oral anticoagulants, aspirin, NSAIDs) |
The antithrombotic exclusion deserves a specific call-out. This isn't just a clinical note — if a member can't safely stop anticoagulation before the implant procedure, Aetna treats them as ineligible. Your surgical team and the prescribing ophthalmologist need to assess and document this before you submit for precertification. If it's borderline, involve your compliance officer.
Coverage Indications at a Glance
| Indication | Status | Relevant Codes | Notes |
|---|---|---|---|
| Idiopathic Macular Telangiectasia Type 2 (MacTel) — adult members | Covered | J3403, CPT 67027 | One-time implantation per affected eye; GCIT precertification required; GCIT network site required |
| MacTel with any of the 17 exclusion criteria present | Not Covered | — | Any single exclusion disqualifies the member |
| Neovascular MacTel (with hemorrhage, subretinal/intraretinal fluid) | Not Covered | — | Intraretinal or subretinal neovascularization is an explicit exclusion |
| Pediatric members | Not Covered | — | Policy covers adults only |
| Repeat Encelto treatment in previously treated eye(s) | Not Covered | — | One-time implantation limit per affected eye |
| Members on active chemotherapy | Not Covered | J8501–J9999 | Chemotherapy is an exclusion comorbidity |
Aetna Encelto Billing Guidelines and Action Items 2025
The effective date of December 20, 2025 is already here. If you have cases in your pipeline, these steps aren't optional.
| # | Action Item |
|---|---|
| 1 | Confirm GCIT network status for your facility now. Check the Aetna Institutes® GCIT Designated Networks list before scheduling any Encelto procedure. This is a hard site-of-care requirement. A claim billed from a non-designated facility will not survive review. |
| 2 | Initiate precertification through the GCIT pathway — not standard prior auth. Call (866) 752-7021 or fax (888) 267-3277. Use Aetna's Specialty Pharmacy Precertification SMN forms. Do not use your standard utilization management contact — this routes differently. |
| 3 | Run every patient against the 17-point exclusion checklist before submitting. Build this into your ophthalmology intake workflow. Prior anti-VEGF treatment, prior vitrectomy (CPT 67036–67043), prior keratoplasty (CPT 65730, 65750, 65755), trabeculectomy (CPT 66170, 66172), trabeculoplasty (CPT 65855), YAG laser (CPT 66821), and lens removal are all chart-documentable. Pull the records before precertification — not after a denial. |
| 4 | Bill J3403 with CPT 67027 for the implantation procedure. HCPCS J3403 (revakinagene taroretcel-lwey, per implant) is the covered code when all selection criteria are met. CPT 67027 covers implantation of an intravitreal drug delivery system and is the procedure code that matches the implant. Verify your charge capture links these two codes correctly. |
| 5 | Document antithrombotic status explicitly in the medical record. Aetna requires that the member is able to temporarily stop anticoagulation, aspirin, or NSAIDs before surgery. This needs to be in the chart — not just in a surgeon's head. A precertification denial on this basis is hard to overturn without clear documentation. |
| 6 | Check the member's plan design for GCIT opt-out provisions. Some Aetna plan designs have elected not to require the GCIT network. Confirm the specific plan's requirements before scheduling. Do not assume the opt-out applies — verify it in the member's benefits. |
| 7 | For Medicare-covered members, stop here and go to Aetna's Medicare Part B criteria. CPB 1079 covers commercial plans only. Medicare criteria are addressed separately. Billing Encelto billing under commercial CPB 1079 criteria against a Medicare claim creates a compliance risk. If your mix includes Medicare Advantage through Aetna, confirm which criteria apply to that population. |
| Previous Version | Current Version |
|---|---|
| Coverage is considered experimental and investigational for all indications | Coverage is considered medically necessary when specific criteria are met |
| Prior authorization is not required | Prior authorization is required for initial treatment |
| Documentation must include clinical history | Documentation must include clinical history |
| Re-review every 24 months | Re-review every 12 months with updated clinical documentation |
CPT, HCPCS, and ICD-10 Codes for Encelto Under CPB 1079
HCPCS Codes — Covered When Selection Criteria Are Met
| Code | Type | Description |
|---|---|---|
| J3403 | HCPCS | Revakinagene taroretcel-lwey, per implant |
CPT and HCPCS Codes — Other Codes Related to CPB 1079
These codes appear in the policy as related procedures. Many of them are relevant to the exclusion criteria — prior procedures billed under these codes may disqualify a member from Encelto coverage.
| Code | Type | Description |
|---|---|---|
| 65730 | CPT | Keratoplasty (corneal transplant); penetrating (except in aphakia or pseudophakia) |
| 65750 | CPT | Keratoplasty (corneal transplant); penetrating (in aphakia) |
| 65755 | CPT | Keratoplasty (corneal transplant); penetrating (in pseudophakia) |
| 65855 | CPT | Trabeculoplasty by laser surgery |
| 66170 | CPT | Fistulization of sclera for glaucoma; trabeculectomy ab externo in absence of previous surgery |
| 66172 | CPT | Fistulization of sclera for glaucoma; trabeculectomy ab externo with scarring from previous ocular surgery |
| 66821 | CPT | Discission of secondary membranous cataract (opacified posterior lens capsule and/or anterior hyaloid) |
| 67027 | CPT | Implantation of intravitreal drug delivery system (e.g., ganciclovir implant), includes concomitant removal of vitreous |
| 67028 | CPT | Intravitreal injection of a pharmacologic agent (separate procedure) |
| 67036 | CPT | Vitrectomy, mechanical, pars plana approach |
| 67037 | CPT | Vitrectomy, mechanical, pars plana approach |
| 67038 | CPT | Vitrectomy, mechanical, pars plana approach |
| 67039 | CPT | Vitrectomy, mechanical, pars plana approach |
| 67040 | CPT | Vitrectomy, mechanical, pars plana approach |
| 67041 | CPT | Vitrectomy, mechanical, pars plana approach |
| 67042 | CPT | Vitrectomy, mechanical, pars plana approach |
| 67043 | CPT | Vitrectomy, mechanical, pars plana approach |
| J0178 | HCPCS | Injection, aflibercept, 1 mg |
| J1095 | HCPCS | Injection, dexamethasone 9%, intraocular, 1 microgram |
| J1096 | HCPCS | Dexamethasone, lacrimal ophthalmic insert, 0.1 mg |
| J2778 | HCPCS | Injection, ranibizumab, 0.1 mg |
| J2779 | HCPCS | Injection, ranibizumab, via intravitreal implant (Susvimo), 0.1 mg |
| J7311 | HCPCS | Injection, fluocinolone acetonide, intravitreal implant (Retisert), 0.01 mg |
| J7312 | HCPCS | Injection, dexamethasone, intravitreal implant, 0.1 mg |
| J7313 | HCPCS | Injection, fluocinolone acetonide, intravitreal implant (Iluvien), 0.01 mg |
| J7314 | HCPCS | Injection, fluocinolone acetonide, intravitreal implant (Yutiq), 0.01 mg |
| J8501–J9999 | HCPCS | Chemotherapy drugs (active chemotherapy is a disqualifying exclusion) |
| Q5155 | HCPCS | Injection, aflibercept-jbvf (Yesafili), biosimilar, 1 mg |
Key ICD-10-CM Diagnosis Codes
The policy lists 344 ICD-10-CM codes. The following are the primary categories directly relevant to Encelto coverage and the exclusion criteria.
| Code | Description |
|---|---|
| B00.50–B00.59 | Herpesviral ocular disease (exclusion — history of ocular herpes disqualifies member) |
| E10.3211–E10.3499 | Type 1 diabetes mellitus with mild, moderate, or severe nonproliferative diabetic retinopathy (exclusion — severe nonproliferative or proliferative DR disqualifies member) |
| E10.3511–E10.3549 | Type 1 diabetes mellitus with proliferative diabetic retinopathy (exclusion) |
| E10.3550–E10.3599 | Type 1 diabetes mellitus with proliferative diabetic retinopathy (exclusion — continued range) |
The full ICD-10-CM code set runs 344 codes and spans diabetic retinopathy across Type 1 and Type 2 diabetes, herpesviral ocular disease, and other conditions relevant to the exclusion criteria. These codes document conditions that disqualify members — they are not covered indication codes. Use them in your chart review and documentation processes to identify ineligible patients before precertification. The complete list is available in CPB 1079 on Aetna's clinical policy site.
Get the Full Picture for CPT 67027
Track this policy across versions, search 1,500+ policies by CPT code, and get real-time alerts when any payer changes coverage.